Loading...
| A02308 | Pages: NA | Dec 2021 | 8202 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Api Intermediate Market
Request Now !API intermediates are compounds or agents used as raw materials for the formulation of active pharmaceutical ingredients (API). Amination, hydrogenation, alkoxylation, hydroformlylation, electrochemisty, acetylene chemistry, phosgene chemistry, and other technologies are used to manufacture these intermediates.
Rise in adoption of generic drugs, speciality medicine, surge in demand for biopharmaceuticals, and increase in abbreviated new drug applications drive the API intermediate market. Furthermore, rise in incidence of diseases and growth in geriatric population prone to various diseases and disorders are anticipated to lead to market growth. R&D activities on development and improvement of drugs for chronic diseases and FDA approvals for new molecules present new opportunities for market expansion. However, stringent government regulations are expected to hinder the market growth.
The API intermediate market is segmented on the basis of product, type of intermediate, therapeutic application, and geography. Based on product, it is bifurcated into chemical intermediates and biotech intermediates. The type of intermediates include patent and non-patent intermediates. Based on therapeutic application, the market is divided into oncology, diabetes, cardiovascular disease, CNS & neurological disorders, endocrinology, and other therapeutic applications. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits
List of players profiled in the report
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 API INTERMEDIATE MARKET, BY PRODUCT
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. CHEMICAL INTERMEDIATES
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. BIOTECH INTERMEDIATES
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
CHAPTER 5 API INTERMEDIATE MARKET, BY TYPE OF INTERMEDIATE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. PATENT INTERMEDIATES
5.2.1. Market size and forecast
5.3. NON-PATENT INTERMEDIATES
5.3.1. Market size and forecast
CHAPTER 6 API INTERMEDIATE MARKET, BY THERAPEUTIC APPLICATION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. ONCOLOGY
6.2.1. Market size and forecast
6.3. DIABETES
6.3.1. Market size and forecast
6.4. CARDIOVASCULAR DISEASE
6.4.1. Market size and forecast
6.5. CNS AND NEUROLOGICAL DISORDERS
6.5.1. Market size and forecast
6.6. ENDOCRINOLOGY
6.6.1. Market size and forecast
6.7. OTHER THERAPEUTIC APPLICATIONS
6.7.1. Market size and forecast
CHAPTER 7 API INTERMEDIATE MARKET, BY GEOGRAPHY
7.1. OVERVIEW
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast
7.2.4. North America API Intermediate Market by Product
7.2.5. North America API Intermediate Market by Type of Intermediate
7.2.6. North America API Intermediate Market by Therapeutic Application
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast
7.3.4. Europe API Intermediate Market by Product
7.3.5. Europe API Intermediate Market by Type of Intermediate
7.3.6. Europe API Intermediate Market by Therapeutic Application
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. India market size and forecast
7.4.3.4. Rest of Asia-Pacific market size and forecast
7.4.4. Asia-Pacific API Intermediate Market by Product
7.4.5. Asia-Pacific API Intermediate Market by Type of Intermediate
7.4.6. Asia-Pacific API Intermediate Market by Therapeutic Application
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.3.1. Latin America market size and forecast
7.5.3.2. Middle East market size and forecast
7.5.3.3. Africa market size and forecast
7.5.4. LAMEA API Intermediate Market by Product
7.5.5. LAMEA API Intermediate Market by Type of Intermediate
7.5.6. LAMEA API Intermediate Market by Therapeutic Application
CHAPTER 8 COMPANY PROFILES
8.1. BASF CORPORATION
8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments
8.2. JIGS CHEMICAL
8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments
8.3. SANOFI WINTHROP INDUSTRIE S.A.
8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments
8.4. AMI LIFE SCIENCES PVT. LTD.
8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments
8.5. CAMBREX CORPORATION
8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments
8.6. A R LIFE SCIENCES PVT LTD.
8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments
8.7. DRAGON HWA CHEMPHARM. CO., LTD.
8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments
8.8. SHANDONG JIULONG FINE CHEMICAL CO., LTD
8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments
8.9. HIPHARMA LIMITED
8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments
8.10. AMPAC FINE CHEMICALS
8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
